AC
FBIO icon

Armistice Capital’s Fortress Biotech FBIO Stock Holding History

Armistice Capital’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-596,000
Closed -$1.79M – 364
2023
Q4 		$1.79M Buy
+596,000
New +$1.58M 0.02% 158

Other funds holding FBIO

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SAM
Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Corient Private Wealth
Corient Private Wealth Miami, Florida $72.2B AUM 27.85% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Armistice Capital's FBIO Position: Q1 2024 in Review

Armistice Capital sold out of Fortress Biotech (FBIO) in Q1 2024, closing a stake of 596,000 shares — an estimated $1.79M sold.

Armistice Capital first reported a position in FBIO in Q4 2023 and held it in 1 quarter. The position peaked at $1.79M in Q4 2023. 40 funds tracked by Wall St. Rank hold FBIO as of Q1 2024.

  • Armistice Capital reported no remaining Fortress Biotech position as of Q1 2024 after selling out during the quarter.
  • Armistice Capital sold 596,000 Fortress Biotech shares in Q1 2024, an estimated $1.79M.
  • Armistice Capital first reported a position in Fortress Biotech in Q4 2023 and held it in 1 quarter.
  • Armistice Capital's Fortress Biotech position peaked at $1.79M in Q4 2023.
  • 40 funds tracked by Wall St. Rank held Fortress Biotech as of Q1 2024.

Based on Armistice Capital's 13F filing for Q1 2024, filed 15 May 2024.